000127803 001__ 127803
000127803 005__ 20240228140950.0
000127803 0247_ $$2doi$$a10.1111/bjh.13652
000127803 0247_ $$2pmid$$apmid:26449739
000127803 0247_ $$2ISSN$$a0007-1048
000127803 0247_ $$2ISSN$$a1365-2141
000127803 0247_ $$2altmetric$$aaltmetric:4721114
000127803 037__ $$aDKFZ-2017-03825
000127803 041__ $$aeng
000127803 082__ $$a610
000127803 1001_ $$aWitzens-Harig, Mathias$$b0
000127803 245__ $$aRituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.
000127803 260__ $$aOxford [u.a.]$$bWiley-Blackwell55962$$c2015
000127803 3367_ $$2DRIVER$$aarticle
000127803 3367_ $$2DataCite$$aOutput Types/Journal article
000127803 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524142512_24091
000127803 3367_ $$2BibTeX$$aARTICLE
000127803 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127803 3367_ $$00$$2EndNote$$aJournal Article
000127803 520__ $$aIn the multicentre prospective randomized HD2002 trial, rituximab maintenance therapy (375 mg/m(2) every 3 months for 2 years) versus observation was evaluated for CD20(+) B-cell lymphoma. Out of 321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets were evaluable for statistical analysis. Estimated 5-year relapse-free survival (RFS) was 81% in the TG and 70% in the OG (logrank test, P = 0·047). In the diffuse large B-cell lymphoma (DLBCL) subgroup (n = 152), 5-year RFS was excellent, at 87% in the TG and 84% in the OG (logrank test, P = 0·35). Of note, only in male patients of the DLBCL subgroup was RFS significantly superior in the TG in comparison to the OG (5-year RFS: 88% vs. 74%; logrank test, P = 0·05). Cox regression analysis showed a significant interaction between treatment and gender regarding overall survival (OS) (P = 0·006) and RFS (P = 0·02), with a lower hazard in females than males in the OG [OS: hazard ratio (HR) (female:male) = 0·11; 95% confidence interval (CI) = 0·00-1·03; RFS: HR (female:male) = 0·27; 95% CI = 0·05-0·97], and no significant differences between males and females in the TG. We conclude that Rituximab maintenance therapy improves survival in male patients with DLBCL.
000127803 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000127803 588__ $$aDataset connected to CrossRef, PubMed,
000127803 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000127803 650_7 $$04F4X42SYQ6$$2NLM Chemicals$$aRituximab
000127803 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b1$$udkfz
000127803 7001_ $$aMcClanahan, Fabienne$$b2
000127803 7001_ $$aKlemmer, Jennifer$$b3
000127803 7001_ $$aBrandt, Julia$$b4
000127803 7001_ $$aBrants, Elke$$b5
000127803 7001_ $$aRieger, Michael$$b6
000127803 7001_ $$aMeissner, Julia$$b7
000127803 7001_ $$aHensel, Manfred$$b8
000127803 7001_ $$0P:(DE-HGF)0$$aNeben, Kai$$b9
000127803 7001_ $$aDreger, Peter$$b10
000127803 7001_ $$aLengfelder, Eva$$b11
000127803 7001_ $$aSchmidt-Wolf, Ingo$$b12
000127803 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b13$$udkfz
000127803 7001_ $$aHo, Anthony D$$b14
000127803 773__ $$0PERI:(DE-600)1475751-5$$a10.1111/bjh.13652$$gVol. 171, no. 5, p. 710 - 719$$n5$$p710 - 719$$tBritish journal of haematology$$v171$$x0007-1048$$y2015
000127803 909CO $$ooai:inrepo02.dkfz.de:127803$$pVDB
000127803 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127803 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000127803 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000127803 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000127803 9141_ $$y2015
000127803 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J HAEMATOL : 2015
000127803 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127803 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127803 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127803 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127803 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127803 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127803 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127803 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127803 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127803 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127803 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127803 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127803 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J HAEMATOL : 2015
000127803 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000127803 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x1
000127803 980__ $$ajournal
000127803 980__ $$aVDB
000127803 980__ $$aI:(DE-He78)C060-20160331
000127803 980__ $$aI:(DE-He78)G330-20160331
000127803 980__ $$aUNRESTRICTED